Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients

• Published in: PloS one Vol. 9; no. 10; p. e109648
• Main Authors: Rabizadeh, Esther, Cherny, Izhack, Wolach, Ofir, Sherman, Shany, Binkovski, Natalia, Peretz, Alon, Lederfein, Doron, Inbal, Aida
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.10.2014; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Angiogenesis; B cells; B-cell lymphoma; Biology and Life Sciences; Biomarkers - metabolism; Blood; Cancer; Cell Membrane - metabolism; Dehydrogenases; Dendritic cells; Female; Fgl2 protein; Fibrin; Fibrinogen; Fibrinogen - metabolism; Gene expression; Hematology; Histology; Humans; Laboratories; Leukocytes (mononuclear); Leukocytes, Mononuclear - metabolism; Lymphocytes; Lymphocytes B; Lymphoma; Lymphoma, B-Cell - metabolism; Lymphoma, B-Cell - pathology; Male; Medical diagnosis; Medical research; Medicine; Medicine and Health Sciences; Membrane proteins; Middle Aged; Non-Hodgkin's lymphomas; Oncology; Patients; Peripheral blood mononuclear cells; Proteins; Prothrombinase; Remission; Research and Analysis Methods; Thromboplastin - metabolism; Thrombosis; Tissues; Tel Aviv Israel; Israel
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0109648

Fibrinogen-like protein 2, FGL-2, was reported to be overexpressed in various cancer tissues, where it acts as a transmembrane prothrombinase. This study aims to determine the prothrombinase activity of FGL-2 in peripheral blood mononuclear cells (PBMC) of patients with B-cell lymphoma. FGL-2 activity was determined in patients with B-cell lymphoma (n = 53), and healthy controls (n = 145). FGL-2 activity in patients at diagnosis increased 3 ± 0.3 fold (p < 0.001). Sensitivity and specificity of the test was established at 73.6% and 80.7%, respectively, using a cutoff of 150% activity over control. Moreover, FGL-2 activity in 10 of 11 patients in remission decreased by 76%. In contrast, no significant difference was observed in expression levels of fgl-2 gene in patients and controls. Taken together, our study indicates that FGL-2 prothrombinase activity in PBMC of lymphoma patients is increased in active disease and normalizes during remission, thus being a potential marker for follow up of lymphoma patients.